354 related articles for article (PubMed ID: 35089534)
1. New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.
Villani A; Potestio L; Fabbrocini G; Scalvenzi M
Adv Ther; 2022 Mar; 39(3):1164-1178. PubMed ID: 35089534
[TBL] [Abstract][Full Text] [Related]
2. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
[TBL] [Abstract][Full Text] [Related]
3. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
[TBL] [Abstract][Full Text] [Related]
4. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
[TBL] [Abstract][Full Text] [Related]
5. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
6. Advanced basal cell carcinoma: What dermatologists need to know about treatment.
Wilson M; Johnson RP; Senft SC; Pan EY; Krakowski AC
J Am Acad Dermatol; 2022 Jun; 86(6S):S14-S24. PubMed ID: 35577406
[TBL] [Abstract][Full Text] [Related]
7. New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer.
Savoia P; Cremona O; Fava P
Curr Drug Targets; 2016; 17(3):353-74. PubMed ID: 26245477
[TBL] [Abstract][Full Text] [Related]
8. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
[TBL] [Abstract][Full Text] [Related]
9. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage.
Zhu GA; Sundram U; Chang AL
JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
11. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer.
Chen L; Aria AB; Silapunt S; Migden MR
Dermatol Surg; 2019 Jan; 45(1):1-16. PubMed ID: 30045105
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer.
Aboul-Fettouh N; Kubicki SL; Chen L; Silapunt S; Migden MR
Dermatol Clin; 2023 Jan; 41(1):23-37. PubMed ID: 36410980
[TBL] [Abstract][Full Text] [Related]
13. The Landmark Series: Non-melanoma Skin Cancers.
Lee AY; Berman RS
Ann Surg Oncol; 2020 Jan; 27(1):22-27. PubMed ID: 31549317
[TBL] [Abstract][Full Text] [Related]
14. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
Ascierto PA; Schadendorf D
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
[TBL] [Abstract][Full Text] [Related]
15. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract][Full Text] [Related]
16. Investigative Landscape in Advanced Non-Melanoma Skin Cancers.
Reddy P; Yao M; Patel M
Curr Treat Options Oncol; 2021 Jun; 22(7):56. PubMed ID: 34097150
[TBL] [Abstract][Full Text] [Related]
17. The Hedgehog pathway and its inhibitors: Emerging therapeutic approaches for basal cell carcinoma.
Jain R; Dubey SK; Singhvi G
Drug Discov Today; 2022 Apr; 27(4):1176-1183. PubMed ID: 34896624
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study).
Ishii M; Hirai I; Tanese K; Fusumae T; Nakamura Y; Fukuda K; Uchi H; Kabashima K; Otsuka A; Yokota K; Yamazaki N; Namikawa K; Fujimura T; Takenouchi T; Yamamoto Y; Nishiguchi M; Sato Y; Amagai M; Funakoshi T
Medicine (Baltimore); 2020 Oct; 99(44):e22913. PubMed ID: 33126349
[TBL] [Abstract][Full Text] [Related]
19. A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature.
Passarelli A; Galdo G; Aieta M; Fabrizio T; Villonio A; Conca R
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202689
[TBL] [Abstract][Full Text] [Related]
20. Cemiplimab for locally advanced and metastatic basal cell carcinoma.
Damsin T; Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2022 Mar; 22(3):243-248. PubMed ID: 35175882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
